Page last updated: 2024-12-08
glucovance
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Glucovance: Glyburide/metformin (Glucovance) for type 2 diabetes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 200105 |
| SCHEMBL ID | 7187343 |
| MeSH ID | M0375183 |
Synonyms (9)
| Synonym |
|---|
| glucovance |
| benzamide, 5-chloro-n-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-, mixt. with n,n-dimethylimidodicarbonimidic diamide monohydrochloride |
| 338752-31-1 |
| glyburide-metformin hydrochloride mixt. |
| glyburide and metformin hydrochloride |
| glyburide-metformin |
| SCHEMBL7187343 |
| DTXSID00187507 |
| 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Blood samples were collected from 24 blood collection sites per cycle for pharmacokinetic analysis until 36 hours after oral administration." | ( Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Chen, L; Huang, J; Huang, X; Li, X, 2023) | 0.91 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " We aimed to compare mortality and cardiovascular risk among users of metformin in combination with pharmacologically different ISs." | ( Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) | 0.42 |
| "Most ISs in combination with metformin were associated with similar mortality and cardiovascular risk." | ( Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) | 0.42 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following an open-label, lead-in phase to optimize the dosing of glyburide/metformin tablets, 365 patients randomly received additive therapy comprising rosiglitazone (4 mg once daily) or placebo for 24 weeks." | ( Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Bruce, S; Dailey, GE; Fiedorek, FT; Noor, MA; Park, JS, 2004) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (69.23) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 86.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (86.85) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (25.81%) | 5.53% |
| Reviews | 5 (16.13%) | 6.00% |
| Case Studies | 2 (6.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (51.61%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||